v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash Flows from Operating Activities    
Net income $ 254 $ 232
Adjustments to reconcile net income to net cash flows provided by operating activities:    
Depreciation 73 70
Amortization 93 103
Impairment of assets 0 9
Acquired in-process research and development and milestones 1 6
Accretion and changes in fair value in contingent consideration 4 23
Deferred income tax expense (benefit) 19 (7)
Stock-based compensation 44 46
Unrealized foreign exchange (gain) loss (9) 1
Gain on sale of Jada (81) 0
Gain on debt repurchase 0 (46)
Other 17 44
Net changes in assets and liabilities, net of assets acquired    
Accounts receivable (176) (76)
Inventories (24) (31)
Other current assets (91) (78)
Trade accounts payable 106 (109)
Accrued and other current liabilities 75 (59)
Income taxes payable 3 46
Other 24 121
Net Cash Flows Provided by Operating Activities 332 295
Cash Flows from Investing Activities    
Capital expenditures (79) (71)
Proceeds from sale of property, plant and equipment 0 1
Acquired in-process research and development and milestones (10) (10)
Proceeds from sale of Jada 433 0
Dermavant acquisition, net of cash acquired 0 (75)
Purchase of product rights and asset acquisition (34) (55)
Net Cash Flows Provided by (Used) in Investing Activities 310 (210)
Cash Flows from Financing Activities    
Proceeds from debt 0 430
Repayments of debt (32) (634)
Employee withholding taxes related to stock-based awards (7) (13)
Dividend payments (11) (81)
Net Cash Flows Used in Financing Activities (50) (298)
Effect of Exchange Rate Changes on Cash and Cash Equivalents (34) 137
Net Increase (Decrease) in Cash and Cash Equivalents 558 (76)
Cash and Cash Equivalents, Beginning of Period 574 675
Cash and Cash Equivalents, End of Period $ 1,132 $ 599